trimetrexate has been researched along with Bone Marrow Diseases in 1 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Bone Marrow Diseases: Diseases involving the BONE MARROW.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Trimetrexate is a nonclassical folate antagonist that is active against a number of experimental murine and human tumor cell lines." | 1.28 | Toxicity of the anticancer folate antagonist trimetrexate in rats. ( Graziano, MJ; Kim, SN; MacDonald, JR; Watkins, JR, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Graziano, MJ | 1 |
| Kim, SN | 1 |
| MacDonald, JR | 1 |
| Watkins, JR | 1 |
1 other study available for trimetrexate and Bone Marrow Diseases
| Article | Year |
|---|---|
Toxicity of the anticancer folate antagonist trimetrexate in rats.
Topics: Administration, Oral; Animals; Blood Cell Count; Body Weight; Bone Marrow; Bone Marrow Diseases; Eat | 1992 |